A single center experience with the use of Occlunix septal occluder for closure of atrial septal defects

The Occlunix® septal occluder (OSO) is a new generation double disk occluder device for catheter closure of the secundum atrial septal defect (ASD). Fifty-six consecutive patients who underwent ASD device closure with the OSO between February 2022 and April 2024 were evaluated in this single-center observational study. All procedures were done under transesophageal echocardiography guidance. The OSO was successfully deployed in all patients (technical success 100%). Fifty-five patients had complete closure of the intervened ASD after device closure (procedural success 98.2%). The sole patient with trivial intradevice shunt had complete seal of the defect at 1-month follow-up. There were no device related complications – cardiac, vascular or systemic. During the follow-up period of 32.2 ± 9.1 months, the device position was satisfactory in all, with no complications. The OSO was associated with lower procedural cost than one of the most used conventional ASD occluders used in the country.